Designed for those who dare to defy disease and revolutionize healthcare, Eon is by far the most powerful solution to identify and manage patients at risk for lung cancer. Using superior Computational Linguistics models, Eon captures nodules with 98.95% accuracy and 98.99% precision. EPM tracks and predicts patient follow-up and arms providers with intelligence that saves lives and increases new hospital revenue.

Daniel Welch

Senior Vice President of Business Development

Rose Medical Center

“I was tasked with finding new ways to increase EBITDA, and through my research found that increasing capture of patients with incidental findings in radiology was an overlooked area of opportunity.”

Accelerate EBITDA with the most advanced actionable findings platform. Hospitals across the nation struggle and operate with thin margins. Now, they are losing millions of dollars a day, and seeing EBITDA margins plummet more than 13% year-over-year. A proven way to contest the trend and decrease patient leakage is to embrace a powerful platform that captures actionable findings.

Raleigh White

Director of Imaging Services

Hutchinson Regional Medical Center

“Within just one week, we came across more than 10 patients who are now scheduled and may have been missed if not for Eon.”

Ramp up service lines by closing the gap on patient leakage. Healthcare organizations bleed revenue when they lose patients to out migration. These missed opportunities and inefficiencies cost hospitals more than 10% of their overall revenue and have detrimental effects on patients facing catastrophic disease. Close the gap with Eon EPM by predicting and preventing leakage before it happens.

Amanda Franklin

Manager of Clinical Transformation

Eon

“When I was an Eon client, EPM reduced my workflow by 200% and I spent <3 minutes per patient. Now with Centralized Management, Eon empowers me to improve efficiencies, increase patient adherence, and help catch early-stage lung cancer across the entire country.”

Elevate Your Program with EPM. Building a successful lung cancer program can be challenging. With EPM’s automated data entry and comprehensive toolkit, you have access to an extensive resource library and time-saving tools. This empowers FTEs to prioritize revenue-gaining tasks, ensure adherence, and submit to the LCSR with one-click.

New

Eon Centralized Management. With Eon’s Centralized Management solution, you can offload resource-intensive tasks and focus your efforts on patient care and profit-earning. From mailing letters, to ensuring life-saving exams are scheduled, to following up with referring providers, to deactivating patients appropriately, Eon does all the work for you with a team of highly skilled navigators and clinical experts. This sets your program up for success and allows you to concentrate on growing your bottom line.

Dr. Akrum (Aki) Alzubaidi

Founder and co-CEO

Eon

“As an Interventional Pulmonologist focused on Lung Cancer, I have seen too much suffering from catastrophic disease. What gets me out of bed in the morning is knowing Eon moves fast to identify more disease and save more lives.”

Power Precision with Superior Data Science Models. Not all nodule registration techniques are the same. Computational Linguistics (CL)—Eon’s proprietary data science identification models—empower clients to positively identify and track incidental pulmonary nodules with 98.99% precision. Natural Language Processing (NLP) and Computer Aided Detection (CAD) are other forms of Artificial Intelligence, but are inferior techniques as their accuracy and precision are much lower and are disruptive to clinician workflow.

What is Computational Linguistics? CL is a data science discipline, or a subset of AI, that understands text and the linguistic structure of written English. CL achieves high-precision output with high positive predictive value that limits the number of false positives.

Dr. Scott Skibo

Haywood Regional Medical Center

“As a profession, the most powerful thing we can do is diagnose lung cancer early. By identifying patients at risk for developing lung cancer earlier, Eon is allowing us to do this in a powerful way.”

Know More. Intervene Earlier. The most effective way to reduce lung cancer mortality is by early diagnosis, yet most patients are asymptomatic until the disease has spread. That’s why capturing and tracking incidental nodules, as well as your lung cancer screening population, is so important. With best-in-class technology, Eon EPM ensures longitudinal tracking of all patients, allowing providers to intervene and diagnose at-risk patients earlier, when treatment is most effective.

Heather Heuer

Lung Cancer Patient Navigator

UP Health System – Marquette

“Being able to access a report that is already triaged has really helped me to prioritize the use of my time. It feels good to be proactive rather than reactive when it comes to patient care.”

Eon is proud to be a preferred partner of these established leaders in modern medicine:

Healthcare for you, by you. Eon was founded by renowned Interventional Pulmonologist, Dr. Aki Alzubaidi, who was determined to create sea change in complex patient management. He saw too many patients suffer as a result of the broken, antiquated healthcare system—so he decided to solve the problem himself. Dr. Aki teamed up with clinical and data science experts to take on modern medicine and use advanced technology to revolutionize the way healthcare data is used to defy disease. Today, Eon is a market leader in improving patient care while lowering costs for providers across the country.

“So, first of all, Eon stops siloing data. Instead, Eon gives outcomes. And because they’re able to be predictive, you’re able to be proactive.

Look, if the technology is sh*t, it’s not going to give you the outcomes that you’re hoping for. The beauty of Eon data is that you’re tracking outcomes. That’s the big difference from the old school programming that is all logic-based and doesn’t work. If this, then that.

That’s what differentiates. Logic-based is completely different from what Eon AI and its derivatives are doing.”

Mark Cuban

Ready to identify, track, and improve outcomes for patients at risk for future disease? Get started with your demo and ensure no patient falls through the cracks.